

Product datasheet for **TL310334V**

PMS1 Human shRNA Lentiviral Particle (Locus ID 5378)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	PMS1 Human shRNA Lentiviral Particle (Locus ID 5378)
Locus ID:	5378
Synonyms:	HNPCC3; hPMS1; MLH2; PMSL1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	PMS1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	BC008410 , NM_000534 , NM_001128143 , NM_001128144 , NM_001289408 , NM_001289409 , NR_110332 , NM_001321044 , NM_001321045 , NM_001321046 , NM_001321047 , NM_001321048 , NM_001321049 , NM_001321051 , NM_000534.1 , NM_000534.2 , NM_000534.3 , NM_000534.4 , NM_001128144.1 , NM_001128143.1 , NM_001289408.1 , NM_001289409.1 , BC036376 , BC084548 , BC096330 , BC096331 , BC096332 , BM553209 , BM677668 , BM800196 , NM_001128144.2 , NM_001128143.2 , NM_000534.5
UniProt ID:	P54277
Summary:	This gene encodes a protein belonging to the DNA mismatch repair mutL/hexB family. This protein is thought to be involved in the repair of DNA mismatches, and it can form heterodimers with MLH1, a known DNA mismatch repair protein. Mutations in this gene cause hereditary nonpolyposis colorectal cancer type 3 (HNPCC3) either alone or in combination with mutations in other genes involved in the HNPCC phenotype, which is also known as Lynch syndrome. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).